CCR7 and B-cell chronic lymphocytic leukemia: For example, the use of neutralizing anti-CCR7 antibodies along with ibrutinib would synergistically target CCR7-induced integrin-mediated adhesion to lymphoid stroma (42, 61, 66), thus enhancing drug-promoted CLL cell mobilization from protective lymphoid niches into circulation.